BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 14, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for May 19, 2020

May 19, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 10x Genomics, 20/20 Genesystems, AACC, Adaptas Solutions, Avero Diagnostics, Biodesix, Curative, Diaceutics, Diethelmkellersiberhegner, ERT, Flatiron Health, Foundation Medicine, Froedtert, Genentech, Inovalon, Korvalabs, L3harris, Oxford Immunotec Global, Partitalia, Physitrack, Roche, Royal Philips, Rewalk Robotics, Sensor ID, Shanghai Biotechnology Devices, Translational Genomics Institute, Ubiquitome, Viraxclear, Zenitas Healthcare.
Read More

Financings for May 19, 2020

May 19, 2020
Med-tech firms raising money in public or private financings, including: Alcon, Atia Vision, Boston Scientific, Cathvision, Chromacode, Medx Health.
Read More
R&D money

Biopharmas continue to ramp up their R&D spending, analysis finds

May 19, 2020
By Peter Winter
According to an analysis conducted by BioWorld of the first quarter 2020 financial reports filed by the top 100 public biopharmaceutical companies ranked by market cap, and excluding big pharma companies, the amount that was invested in research and development (R&D) during the period increased by 13% compared to the same period last year.
Read More

HHS-industry partnership to ramp up U.S.-based drug manufacturing

May 19, 2020
By Mari Serebrov
Responding to COVID-19’s wakeup call as it exposes the risks of relying heavily on foreign biopharma supply chains, the U.S. Department of Health and Human Services (HHS) signed a four-year, $354 million agreement with a team of private industry partners, led by Phlow Corp., to expand U.S. manufacturing of essential medicines at risk of shortage during the pandemic and in future public health emergencies.
Read More

EMA’s Rasi laments fragmented clinical trial efforts targeting COVID-19

May 19, 2020
By Nuala Moran
LONDON - EMA Director General Guido Rasi has hit out at the lack of coordination in COVID-19 clinical trials, questioning if the huge number of small studies that are running will support regulatory decision-making.
Read More

Moderna tops public biopharma raises with $1.34B to help fund its COVID-19 vaccine

May 19, 2020
By Karen Carey
Representing the highest amount ever raised by a public biopharma company on a U.S. exchange, Moderna Inc. priced a $1.34 billion follow-on offering to help fund worldwide manufacturing and distribution of its mRNA-1273 vaccine for COVID-19.
Read More

Regulatory actions for May 19, 2020

May 19, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Kempharm, Novartis, Organicell, Theralase, Tolero.
Read More

Other news to note for May 19, 2020

May 19, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abnova, Adjuvance, Aetion, Be The Match, Cabaletta, Centivax, Cytodyn, Dyne, Genocea, Match, Haliodx, Imcheck, Innovation Pharmaceuticals, Ipsen, Innovent, Merck & Co., Nantkwest, Onxeo, Oragenics, Pharmajet, Primary Peptides, Prellis, Promis, Qingdao Primedicine, Revance, Rising Pharma, Ritter, Sernova, Shionogi, Sophiris, Therapix, Timber, Xenetic.
Read More

In the clinic for May 19, 2020

May 19, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Agios, Amplyx, Arbutus, Biogen, Covis, Hepion, Lidds, Mezzion, MGB Biopharma.
Read More
Product box for Everlywell's COVID-19 collection kit

FDA authorizes home sample kit for Everlywell, shuts down similar effort in Seattle

May 18, 2020
By Mark McCarty
The FDA has granted an emergency use authorization (EUA) for the home sample collection kit made by Austin, Texas-based Everlywell Inc., which can be run on two lab-developed tests. However, the agency has also shut down a Gates Foundation-backed effort in Seattle to develop another home sample collection kit even though the organization behind the effort has been authorized by state health authorities. The FDA announced the news about the Everlywell EUA with the stipulation that the user of the kit has completed an online questionnaire that is subsequently reviewed by a health care professional.
Read More
Previous 1 2 … 454 455 456 457 458 459 460 461 462 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 14, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • Brain maze

    Alzheimer’s, beyond the brain

    BioWorld
    Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 12, 2026
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing